A few of our speakers have been confirmed! Please check back soon for updates to the lineup, or follow us on social media, or sign up for our newsletter to be notified as we confirm more speakers for the event!
David Nutt, PhD
Professor David Nutt is a British neuropsychopharmacologist, globally renowned for his innovative research on the treatment of anxiety, substance abuse, and sleep disorders. In recent years, Nutt has pioneered psychedelic neuroimaging studies and carried out influential research on the therapeutic application of psilocybin. He is currently an editor of the Journal of Psychopharmacology, president of the European Brain Council, and both the Edmond J Safra Chair in Neuropsychopharmacology and deputy head of the Centre for Psychedelic Research at the Imperial College London. Nutt is the founder of DrugScience, an independent UK-based drugs advisory committee which reviews scientific findings on drug harms. He is a strong advocate of evidence-based drug policy, working tirelessly to bridge the gap between legislators and researchers.
Anja Loizaga-Velder, PhD
Dr. Anja Loizaga-Velder is a German-Mexican clinical psychologist whose research into the therapeutic potential of ritual psychedelic plant use spans more than two decades. She serves as Director of Research and Psychotherapy at the Nierika Institute for Intercultural Medicine and is currently collaborating on the Ayahuasca Treatment Outcome Project, which aims to validate the effectiveness of Ayahuasca and traditional Amazonian medicine for the treatment of addictions. Loizaga-Velder is also an adjunct professor of Humanities in Health at the National Autonomous University of Mexico, where she works to implement clinical research in evaluating the therapeutic efficacy of sacred plants in intercultural therapeutic settings. Her work aims to preserve and amplify the wisdom of precolonial Amazonian and Mesoamerican traditions while cultivating a respectful and productive dialogue between western medicine and indigenous healers.
Matthew W. Johnson, PhD
Dr. Matthew W. Johnson is a professor and Associate Director for the Center for Psychedelics & Consciousness Research at Johns Hopkins University. He has been researching psychedelics since 2004, and his early work played a major role in the resurrection of psychedelic research. In recent years, Dr. Johnson has orchestrated some of the most widely cited studies of psychedelic research including the world’s first clinical investigation into psychedelic treatment of tobacco addiction (2014), as well as the largest study to date on the use of psilocybin as a treatment for cancer-related depression and anxiety (2016). He is a founding member and the current president of the International Society for Research on Psychedelics and has served as president for the Psychopharmacology and Substance Abuse Division of the American Psychological Association. Today, he stands as one of the world’s most published scientists on the human effects of psychedelics, and has conducted seminal research in the behavioral economics of drug use, addiction, and risk behavior.